Patents by Inventor Robert M. Wenslow, Jr.

Robert M. Wenslow, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND USES THEREOF
    Publication number: 20230065636
    Abstract: Pharmaceutical formulations comprising substituted pyrazolopyrimidines are disclosed herein. Also disclosed are amorphous solid dispersions comprising substituted pyrazolopyrimidines, processes for preparing these amorphous solid dispersions, pharmaceutical compositions comprising such dispersions, and methods of use thereof.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 2, 2023
    Inventors: Hanlan LIU, Robert M. WENSLOW, Jr.
  • CRYSTALLINE FORMS OF A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND AND USE THEREOF AS P2X3 MODULATOR
    Publication number: 20220002292
    Abstract: Described herein are crystalline forms of a P2X3 modulator, namely (S)-methyl-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate or a solvate thereof, and use thereof for treating pain, urinary tract disorder, cough, pruritus and endometriosis.
    Type: Application
    Filed: November 12, 2019
    Publication date: January 6, 2022
    Inventors: Denis GARCEAU, Robert M. WENSLOW, Jr., Kemal PAYZA, Nathalie CHAURET
  • Crystal forms of a HCV protease inhibitor
    Patent number: 9242917
    Abstract: The present invention relates to different forms of a HCV inhibitory compound.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 26, 2016
    Assignees: Merck Sharp & Dohme Limited, Merck Sharp & Dohme Corp.
    Inventors: Gregory L Beutner, Robert M Wenslow, Jr., Eric J Choi, Clinton Scott Shultz, Jeremy Scott, Juan D Arredondo, Laura Artino
  • CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR
    Publication number: 20140206605
    Abstract: The present invention relates to different forms of a HCV inhibitory compound.
    Type: Application
    Filed: August 16, 2012
    Publication date: July 24, 2014
    Inventors: Gregory L. Beutner, Robert M. Wenslow, JR., Eric J. Choi, Clinton Scott Shultz, Jeremy Scott, Juan D. Arredondo, Laura Artino
  • Crystalline forms of an inhibitor of 11-?-hydroxysteroid dehydrogenase type 1
    Patent number: 8618112
    Abstract: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: December 31, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph E. Lynch, Yuri Y. Bereznitski, Frederick T. Mattrey, John L. Leazer, Jr., Russell R. Ferlita, Jinchu Liu, Jungjun Yin, Robert M. Wenslow, Jr.
  • NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
    Publication number: 20110237634
    Abstract: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Application
    Filed: December 7, 2009
    Publication date: September 29, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Joseph E. Lynch, Yuri Y. Bereznitski, Frederick T. Mattrey, John L. Leazer, JR., Russell R. Ferlita, Jinchu Liu, Jungjun Yin, Robert M. Wenslow, JR.
  • Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
    Patent number: 7326708
    Abstract: The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: February 5, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Howard Cypes, Alex Minhua Chen, Russell R. Ferlita, Karl Hansen, Ivan Lee, Vicky K. Vydra, Robert M. Wenslow, Jr.